HK1202798A1 - Mesenchymal stromal cells and uses related thereto - Google Patents

Mesenchymal stromal cells and uses related thereto

Info

Publication number
HK1202798A1
HK1202798A1 HK15103332.4A HK15103332A HK1202798A1 HK 1202798 A1 HK1202798 A1 HK 1202798A1 HK 15103332 A HK15103332 A HK 15103332A HK 1202798 A1 HK1202798 A1 HK 1202798A1
Authority
HK
Hong Kong
Prior art keywords
stromal cells
mesenchymal stromal
uses related
mesenchymal
cells
Prior art date
Application number
HK15103332.4A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Lanza
Erin Anne Kimbrel
Jianlin Chu
Nicholas Arthur Kouris
Original Assignee
Advanced Cell Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48536141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202798(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Cell Tech Inc filed Critical Advanced Cell Tech Inc
Publication of HK1202798A1 publication Critical patent/HK1202798A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/141—Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/08—Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/54—Interprogram communication
    • G06F9/542—Event management; Broadcasting; Multicasting; Notifications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00—Aspects of pattern recognition specially adapted for signal processing
HK15103332.4A 2011-11-30 2015-04-01 Mesenchymal stromal cells and uses related thereto HK1202798A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161565358P 2011-11-30 2011-11-30
PCT/US2012/067464 WO2013082543A1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto

Publications (1)

Publication Number Publication Date
HK1202798A1 true HK1202798A1 (en) 2015-10-09

Family

ID=48536141

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103332.4A HK1202798A1 (en) 2011-11-30 2015-04-01 Mesenchymal stromal cells and uses related thereto

Country Status (20)

Country Link
US (4) US8962321B2 (ko)
EP (2) EP3449929A1 (ko)
JP (4) JP2015500810A (ko)
KR (4) KR102525175B1 (ko)
CN (2) CN104136034B (ko)
AU (4) AU2012345630A1 (ko)
CA (1) CA2857545A1 (ko)
CY (1) CY1122275T1 (ko)
DK (1) DK2785359T3 (ko)
ES (1) ES2690212T3 (ko)
HK (1) HK1202798A1 (ko)
HR (1) HRP20181515T1 (ko)
HU (1) HUE040566T2 (ko)
LT (1) LT2785359T (ko)
PL (1) PL2785359T3 (ko)
PT (1) PT2785359T (ko)
RS (1) RS57886B1 (ko)
SI (1) SI2785359T1 (ko)
TW (4) TWI698242B (ko)
WO (1) WO2013082543A1 (ko)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5630781B2 (ja) * 2006-04-14 2014-11-26 アドバンスド セル テクノロジー、インコーポレイテッド 血管コロニー形成細胞
JP5748654B2 (ja) 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA3176706A1 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
ES2615396T3 (es) 2013-08-22 2017-06-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Método para producir músculo cardiaco por ingeniería (EHM)
AU2014348184B2 (en) * 2013-11-18 2020-08-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
JP6800757B2 (ja) * 2014-06-10 2020-12-16 メゾブラスト・インターナショナル・エスアーエールエル 免疫疾患の治療
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
CN104232573B (zh) * 2014-09-11 2017-01-11 安沂华 一种生长培养基及其用途和培养脐带间充质干细胞的方法
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104531613B (zh) * 2014-11-17 2017-12-19 中国农业科学院北京畜牧兽医研究所 Wip1敲除在促进小鼠骨髓间充质干细胞迁移中的应用
KR20170095932A (ko) * 2014-12-23 2017-08-23 메조블라스트 인터내셔널 에스에이알엘 심부전의 치료 방법
IL303401A (en) 2015-03-23 2023-08-01 Astellas Inst For Regenerative Medicine Improved assays for the potential of retinal pigment epithelium (RPE) cells and photoreceptor progenitors
DK3331994T3 (da) * 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd Fremstilling af retinale pigmentepitelceller
AU2016308818B2 (en) 2015-08-18 2022-04-21 Astellas Institute For Regenerative Medicine Clinical formulations
JP2018533370A (ja) * 2015-09-29 2018-11-15 セルラリティ インコーポレイテッド 細胞効力アッセイ
CN108289915A (zh) * 2015-11-24 2018-07-17 日本乐敦制药株式会社 包含脂肪组织来源基质细胞的肝病治疗剂及其制造方法
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
US10383895B2 (en) * 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
CN105671000A (zh) * 2016-03-02 2016-06-15 深圳爱生再生医学科技有限公司 重组间充质干细胞及其制备方法和应用
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
EP3481967A4 (en) * 2016-07-11 2020-04-22 Bonus Therapeutics Ltd. CELL COMPOSITIONS FOR TISSUE REGENERATION
CN106265899A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种组合物及其在制备改善慢性鼻炎的产品中的应用
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
CN106520686A (zh) * 2016-10-11 2017-03-22 海南博鳌龄迈迪精准医学研究院有限公司 脂肪间充质干细胞的培养方法
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
CA3042360A1 (en) * 2016-11-03 2018-05-11 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
CN106563161A (zh) * 2016-11-08 2017-04-19 华南生物医药研究院 可用于美容的新型药物组合剂
CN106619721A (zh) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 一种增强细胞活性的新方法
CN106581760A (zh) * 2016-11-08 2017-04-26 华南生物医药研究院 增强细胞活性的特殊处理方法
KR102390909B1 (ko) * 2016-12-19 2022-04-26 주식회사 파이안바이오테크놀로지 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
US11613733B2 (en) 2017-05-12 2023-03-28 Medical & Biological Laboratories Co., Ltd. Method for purifying mesenchymal stem cells to improve transplantation efficiency
AU2018289935A1 (en) * 2017-06-19 2020-01-23 Life Science Institute, Inc. Treatment agent for epidermolysis bullosa
CN107490701B (zh) * 2017-08-17 2021-09-14 上海集技生物技术有限公司 一种基于局部照射的全身性骨损伤模型的建立及病理机制分析的方法
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CN109069543B (zh) * 2017-10-16 2020-02-18 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
JP2021510805A (ja) * 2017-11-06 2021-04-30 キングス カレッジ ロンドンＫｉｎｇｓ Ｃｏｌｌｅｇｅ Ｌｏｎｄｏｎ 治療物質、それらの調製物及び診断手順
KR102095628B1 (ko) 2018-01-05 2020-04-01 재단법인 아산사회복지재단 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
CN111712565A (zh) * 2018-02-16 2020-09-25 奈科斯特细胞制药有限公司 同种异体组合物
WO2019171386A1 (en) * 2018-03-07 2019-09-12 The Medical Research Infrastructure And Health Services Fund Of The Tel-Aviv Medical Center Compositions and methods for treating age-related macular degeneration
CA3103043A1 (en) * 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN109082409A (zh) * 2018-09-14 2018-12-25 四川新生命干细胞科技股份有限公司 一种组织修复能力强的脂肪干细胞分离培养及筛选方法
CN109182262A (zh) * 2018-09-25 2019-01-11 深圳市五零生命科技有限公司 一种间充质干细胞无血清培养基
CN109342739A (zh) * 2018-11-27 2019-02-15 上海科医联创生物科技有限公司 一种鉴定间充质干细胞纯度的方法
CN109609584A (zh) * 2018-12-10 2019-04-12 天津长和生物技术有限公司 间充质干细胞免疫调节能力的检测方法
EP3931307A1 (en) * 2019-02-27 2022-01-05 TiGenix, S.A.U. Improved stem cell populations for allogeneic therapy
JPWO2020184729A1 (ko) 2019-03-14 2020-09-17
CN110305839A (zh) * 2019-08-02 2019-10-08 陕西佰傲干细胞再生医学有限公司 间充质干细胞无血清培养基
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
CA3151636A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
CN110564674B (zh) * 2019-09-29 2021-05-11 广东工业大学 一种干细胞铺底工作液及其应用
WO2021072595A1 (zh) * 2019-10-14 2021-04-22 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在治疗听力障碍上的医药用途
RU2740152C1 (ru) * 2020-01-09 2021-01-13 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) Способ активации пролиферативного ответа фибробластоподобных клеток стромально-васкулярной фракции жировой ткани
CN114829583A (zh) * 2020-02-25 2022-07-29 上海大学 间充质干细胞在治疗重症covid19肺炎中的用途
CN115297877A (zh) * 2020-04-13 2022-11-04 国立大学法人东海国立大学机构 肾脏中cd25阳性调节性t细胞增加剂
AU2021264523A1 (en) * 2020-04-28 2022-12-08 Factor Bioscience Inc. Mesenchymal stem cell therapies
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
EP3945133A1 (en) * 2020-07-29 2022-02-02 Georg-August-Universität Göttingen Mass production of human pluripotent stem cell derived cardiac stromal cell
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US20230405051A1 (en) * 2020-10-22 2023-12-21 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for prevention or treatment of rheumatoid arthritis, comprising, as active ingredient, stem cells having expression of specific genes increased or decreased therein
JP2024515384A (ja) * 2021-05-07 2024-04-09 スンクワン メディカル ファウンデーション 骨分化能機能強化の間葉系幹細胞、及びその用途
CN113717972B (zh) * 2021-08-16 2022-07-01 南通市肿瘤医院 MYADM靶向的siRNA及其应用
CA3234969A1 (en) * 2021-10-12 2023-04-20 Makoto Funaki Anti-aging composition using mesenchymal stem cells and methods thereof
US20230257714A1 (en) * 2022-02-07 2023-08-17 Smartcella Solutions Ab Methods and compositions for generating human induced mesenchymal stem cells
CN114984051A (zh) * 2022-06-27 2022-09-02 广州惠善医疗技术有限公司 间充质干细胞在制备治疗炎症及免疫相关疾病的药物中的应用
WO2024007038A2 (en) * 2022-07-01 2024-01-04 Northwestern University Compositions and methods for the treatment of intestinal inflammation
WO2024019962A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine Methods of treating brain injury
CN115305234B (zh) * 2022-09-28 2023-01-17 呈诺再生医学科技(北京)有限公司 一种制备间充质干细胞的方法、间充质干细胞和应用
CN116836920A (zh) * 2023-08-21 2023-10-03 佛山市生物医学工程学会 一种无血清培养基及其制备间充质干细胞的方法
CN117210528A (zh) * 2023-09-12 2023-12-12 长沙干细胞与再生医学工业技术研究院有限公司 一种综合评估间充质干细胞免疫调控能力的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6416581A (en) * 1987-07-09 1989-01-20 Rikagaku Kenkyusho Frozen animal cell and production thereof
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
CA2422852C (en) 2000-09-18 2012-06-26 Organogenesis Inc. Methods for treating a patient using a bioengineered flat sheet graft prostheses
US20030027330A1 (en) 2001-04-02 2003-02-06 Robert Lanza Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
DE60233248D1 (de) * 2001-11-15 2009-09-17 Childrens Medical Center Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
EP1490107A4 (en) * 2002-03-21 2005-11-09 Univ Florida MODULATION OF ANGIOGENESIS
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
GB2417961B8 (en) 2003-05-08 2008-05-09 Cellartis Ab Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
CA2852122A1 (en) 2004-01-02 2005-07-28 Advanced Cell Technology, Inc. Novel culture systems for ex vivo development
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2929782A1 (en) 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2566549C (en) * 2004-05-12 2014-01-14 The Walter And Eliza Hall Institute Of Medical Research A method for isolating mammary stem cells
JP2006230316A (ja) * 2005-02-25 2006-09-07 Japan Health Science Foundation 瘢痕のない創傷治癒能を有する細胞およびその調製方法
US20090215640A1 (en) 2005-05-27 2009-08-27 West Michael D Methods for identifying ligands for stem cells and cells derived therefrom
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
EP1984487B1 (en) 2005-08-03 2022-10-12 Astellas Institute for Regenerative Medicine Improved methods of reprogramming animal somatic cells
US20090271335A1 (en) 2005-10-20 2009-10-29 Advanced Cell Technology, Inc. Totipotent, Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes
WO2007062198A1 (en) 2005-11-21 2007-05-31 Advanced Cell Technology, Inc. Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
WO2007093412A2 (en) * 2006-02-16 2007-08-23 Fondazione Centro San Raffaele Del Monte Tabor Skeletal muscle periangioblasts and cardiac mesoangioblasts, method for isolation and uses thereof
WO2007099337A1 (en) * 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
JP5630781B2 (ja) * 2006-04-14 2014-11-26 アドバンスド セル テクノロジー、インコーポレイテッド 血管コロニー形成細胞
KR100791487B1 (ko) * 2006-05-29 2008-01-03 연세대학교 산학협력단 제대혈로부터 간엽줄기세포의 분리 및 배양 방법
EP3190178A1 (en) 2007-02-23 2017-07-12 Astellas Institute for Regenerative Medicine Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
KR101039235B1 (ko) * 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US20110236971A2 (en) 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
CA3006687C (en) 2007-10-12 2024-01-09 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
WO2009104825A1 (en) * 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
JP5748654B2 (ja) * 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
KR20110013450A (ko) * 2008-05-07 2011-02-09 본 테라퓨틱스 소시에테아노님 간엽 줄기 세포 및 골-형성 세포
JP2011529706A (ja) * 2008-08-04 2011-12-15 アローキュア インコーポレイテッド 間充織間質細胞集団、ならびにそれを単離および使用する方法
EP2221362A1 (en) 2009-02-19 2010-08-25 Naturin GmbH & Co Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies
JP2010252778A (ja) * 2009-04-02 2010-11-11 Shizui Bank Kk 歯髄由来間葉系幹細胞の分離方法及び分離した幹細胞並びにそれらを用いた肝細胞系譜への分化
US20110195054A1 (en) * 2009-10-06 2011-08-11 Michael Cohen Preparation And Use Of Stromal Cells For Treatment Of Cardiac Diseases
WO2011053860A2 (en) 2009-10-30 2011-05-05 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
US8900860B2 (en) * 2009-11-30 2014-12-02 National Yang-Ming University Method for expanding mesenchymal stem cells in low-density and hypoxic culture
AU2011213081A1 (en) * 2010-02-02 2012-08-23 University Of Rochester Methods of isolating and culturing mesenchymal stem cells
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
EP3679939A1 (en) * 2010-10-08 2020-07-15 Mesoblast International Sàrl Enhanced msc preparations
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
WO2014011407A2 (en) * 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

Also Published As

Publication number Publication date
CN108478599B (zh) 2022-08-02
KR20210044904A (ko) 2021-04-23
KR102108245B1 (ko) 2020-05-08
AU2017239526A1 (en) 2017-10-26
KR20230059838A (ko) 2023-05-03
HRP20181515T1 (hr) 2018-11-16
WO2013082543A1 (en) 2013-06-06
CY1122275T1 (el) 2020-07-31
KR102525175B1 (ko) 2023-04-21
US20210182552A1 (en) 2021-06-17
CN108478599A (zh) 2018-09-04
TWI698527B (zh) 2020-07-11
TW201331365A (zh) 2013-08-01
TW202344258A (zh) 2023-11-16
RS57886B1 (sr) 2019-01-31
CA2857545A1 (en) 2013-06-06
DK2785359T3 (en) 2018-10-29
KR102246369B1 (ko) 2021-04-29
TWI698242B (zh) 2020-07-11
ES2690212T3 (es) 2018-11-19
JP2018027954A (ja) 2018-02-22
EP2785359A4 (en) 2015-11-11
KR20200051827A (ko) 2020-05-13
AU2022202639A1 (en) 2022-05-12
JP2022027796A (ja) 2022-02-14
TW201815399A (zh) 2018-05-01
JP6526130B2 (ja) 2019-06-05
HUE040566T2 (hu) 2019-03-28
JP6983195B2 (ja) 2021-12-17
US8962321B2 (en) 2015-02-24
AU2019264631B2 (en) 2022-01-20
LT2785359T (lt) 2018-11-12
TWI812867B (zh) 2023-08-21
US20160038543A1 (en) 2016-02-11
JP2019142958A (ja) 2019-08-29
CN104136034B (zh) 2018-04-24
US20130183272A1 (en) 2013-07-18
KR20140127209A (ko) 2014-11-03
JP2015500810A (ja) 2015-01-08
SI2785359T1 (sl) 2018-11-30
EP2785359B1 (en) 2018-08-29
EP2785359A1 (en) 2014-10-08
EP3449929A1 (en) 2019-03-06
TW202037373A (zh) 2020-10-16
US20170252374A1 (en) 2017-09-07
AU2017239526B2 (en) 2019-08-15
CN104136034A (zh) 2014-11-05
PT2785359T (pt) 2018-11-06
PL2785359T3 (pl) 2018-12-31
AU2019264631A1 (en) 2019-12-05
AU2012345630A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
HRP20181515T1 (hr) Mezenhimne stromalne stanice i upotreba povezana s njima
HK1211623A1 (en) Cell lines
HK1199905A1 (en) Culturing of mesenchymal stem cells
SI2564880T1 (sl) Celični konstrukt za celično transplantacijo in celični agregat za celično transplantacijo
SG11201503579RA (en) Cell culture med
EP2895594A4 (en) ELECTROSYNTHETIC MICROBIAL CELLS
HK1207121A1 (en) Cell culturing device
SI2758523T1 (sl) Stromalne matične celice
SG11201500417PA (en) Cell culture
EP2698839A4 (en) BLOCK OF CELLS
EP2911230A4 (en) CELL
GB201017421D0 (en) Cell
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2709204A4 (en) OXYGEN CELL
EP2665811A4 (en) SOMATIC CELLS WITH POTENTIAL INNÉ OF PLURIPOTENCE
SG11201403280PA (en) Bioreactor
EP2830138A4 (en) BIO FUEL CELL
EP2863459A4 (en) FLAT CELL
GB2503032B (en) Serviceable bioreactor
GB2500031B (en) Fuel cells
GB201211873D0 (en) Cell culture
PL2776552T3 (pl) Urządzenie do hodowli komórek
GB201213450D0 (en) Cell culture devices
GB201119658D0 (en) Cell
GB201218496D0 (en) Cell